The 2024 Hong Kong International Biotech Forum & Exhibition (BIOHK 2024) is scheduled to be held grandly from September 11 to 14 at the Hong Kong Convention and Exhibition Centre. This prestigious event is jointly organized by the Hong Kong Biotechnology Organization, Vantage Capital Limited, the Baihua Association, and the Chinese Society for Biotechnology, with strong support from co-organizers such as the Asian Cancer Research Foundation.

Professor Yu Changhai, Chairman of the Hong Kong Biotechnology Organization and one of the host entities, specifically highlighted that this year's forum will continue to adopt the theme from the previous edition: "Kaleidoscope." This theme profoundly symbolizes the extensive scope of the biotechnology sector and the deep interdisciplinary convergence within it.

On the opening day of the exhibition, numerous distinguished guests graced the event, including Mr. Leung Chun-ying, Vice Chairman of the National Committee of the Chinese People's Political Consultative Conference; Mr. Sun Dong, Secretary for Innovation, Technology and Industry of the Hong Kong Special Administrative Region Government; and Professor Lo Yuk-lun, Honorary Chairman of the Hong Kong Biotechnology Organization. Together with partners from many renowned global enterprises, they jointly witnessed the grand opening of the forum.

Professor Shi Yuanyuan, Chairman of Shenzhen Cell Valley, attended the event at the invitation of Professor Yu Changhai, Chairman of the Conference and President of the Hong Kong Biotechnology Organization. Prof. Shi delivered a keynote English speech titled "Innovation and Industrialization of Cell Therapy Technology" and participated in the Expert Forum, accompanied by Dr. Fu Yuchen, Assistant to the Chairman of our company. During the Expert Forum, Prof. Shi engaged in an in-depth and rigorous discussion with attending experts on the topic of deeply integrating general industrial development with clinical industrialized production in the Hong Kong region.

As the only domestic provider offering a one-stop solution for cell and gene therapy featuring industrial-grade retroviral vectors, Shenzhen Cell Valley has established a solid industry position in the field of cell and gene therapy, underpinned by its exceptional core technological capabilities. Recently, the company achieved a major breakthrough in the research and development of a novel gene editing delivery system. Meeting the high standards required for the safety and efficacy of cell therapy products, this system has already facilitated the establishment of strategic partnerships with multiple authoritative medical institutions across China. These collaborations aim to jointly drive the overall progress and development of the cell and gene therapy industry.

Through this forum, our company will fully leverage Hong Kong's unique advantages as an international platform to showcase China's remarkable achievements in innovative technologies and their commercialization to the global community. Furthermore, by making a presence at this world-class forum, we aim to further advance our internationalization strategy and open a new chapter for global exchange and cooperation.

Mr. Yu Changhai, Chairman of the Hong Kong Biotechnology Organization, poses for a photo with Chairman Professor Shi Yuanyuan.